ArticleBioactive materials2026
Spatiotemporal delivery of exosomes and alendronate orchestrates osteoblastic and osteoclastic activity for osteoporotic bone regeneration.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of bone defects in osteoporotic (OP) patients remain a significant clinical challenge. The most important and challenging task is to promote sufficient bone formation in the early stage and effectively inhibit bone resorption all period of bone healing. Unfortunately, the efficacy of current strategies falls short of meeting this requirement. In this study, we developed a dual-delivery system that allows spatiotemporal release of bone marrow stem cell-derived exosomes (BMSC-Exo) and alendronate (Aln) by core-shell nanofiber to match the spatiotemporal dynamics of bone healing and effectively treat OP bone defects. Core-shell polycaprolactone/polyvinyl alcohol (P/PVA) nanofibers were fabricated through coaxial electrospinning, incorporating Aln within the core layer and BMSC-Exo functionalized onto the surface of nanofiber via chemical modification with polyethyleneimine (PEI). Physicochemical characterization confirmed the successful fabrication of PEI@P/PVA-Aln nanofibers, which exhibited excellent mechanical strength (22.77 MPa), hydrophilicity (9.66°), and enabled the spatiotemporal release of BMSC-Exo and Aln. In vitro experiments showed that Exo-PEI@P/PVA-Aln scaffold effectively promoted osteogenic differentiation by miR-486 in the BMSC-Exo through regulation of the PTEN/AKT signaling axis and significantly reduced osteoclastic differentiation. Under a rat OP cranial defect model, the Exo-PEI@P/PVA-Aln scaffold demonstrated substantially enhanced bone repair efficiency after 4 and 10 weeks. To conclude, our results showed that the dual delivery of BMSC-Exo and Aln with spatiotemporal release orchestrates osteoblastic and osteoclastic activity, providing a potential strategy to facilitate the regeneration of OP bone defects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.